Mati Therapeutics
Biotechnology company based in Austin, Texas developing a non-invasive sustained ocular drug delivery platform that uses a punctal plug implanted in the tear duct to deliver medication to the tear film over extended periods. The company has completed multiple Phase II clinical trials across indications (post-operative pain/inflammation, glaucoma, allergy), is advancing candidates into Phase III, operates a dedicated manufacturing facility for the platform, and maintains an extensive international patent portfolio covering the delivery technology.
Industries
Nr. of Employees
small (1-50)
Mati Therapeutics
Patents
Drug delivery methods, structures, and compositions for nasolacrimal system
US-11406592-B2
View Details
Drug delivery methods, structures, and compositions for nasolacrimal system
US-11406592-B2
View DetailsProducts
Punctal plug-based sustained ocular drug delivery system
A minimally invasive implantable punctal plug containing a customizable drug-eluting core designed to release medication into the tear film over extended periods to treat ocular conditions.
Clinical-stage molecule candidates formulated for punctal plug delivery
Specific pipeline candidates formulated for the punctal plug delivery system, including an NSAID for post-cataract pain, steroids for inflammation, and prostaglandin analogues for glaucoma.
Evolute Punctal Plug Drug Delivery System
A small, comfortable and cosmetically invisible device that automatically delivers the required medication to the patient for an extended period of time eliminating the need for patients or care givers to administer eye drops.
Punctal plug-based sustained ocular drug delivery system
A minimally invasive implantable punctal plug containing a customizable drug-eluting core designed to release medication into the tear film over extended periods to treat ocular conditions.
Clinical-stage molecule candidates formulated for punctal plug delivery
Specific pipeline candidates formulated for the punctal plug delivery system, including an NSAID for post-cataract pain, steroids for inflammation, and prostaglandin analogues for glaucoma.
Evolute Punctal Plug Drug Delivery System
A small, comfortable and cosmetically invisible device that automatically delivers the required medication to the patient for an extended period of time eliminating the need for patients or care givers to administer eye drops.
Services
On-site production capacity for development and commercial supplies of punctal plug delivery products using automated, robotic multi-step manufacturing processes.
Formulation development and CMC support for molecules intended for incorporation into sustained-release punctal plug cores, including liposome, emulsion and lyophilized approaches.
Clinical program planning and execution for ophthalmic indications, including multi-center randomized masked trials and endpoint evaluation (pain, inflammation, visual acuity).
On-site production capacity for development and commercial supplies of punctal plug delivery products using automated, robotic multi-step manufacturing processes.
Formulation development and CMC support for molecules intended for incorporation into sustained-release punctal plug cores, including liposome, emulsion and lyophilized approaches.
Clinical program planning and execution for ophthalmic indications, including multi-center randomized masked trials and endpoint evaluation (pain, inflammation, visual acuity).
Expertise Areas
- Ocular drug delivery
- Sustained-release formulation development
- Clinical trial management (multi-center randomized trials)
- Formulation and process development (topical, ocular, oral, parenteral)
Key Technologies
- Punctal plug-based ocular drug delivery
- Drug-eluting sustained-release cores
- Ocular formulation technologies (topical/ocular NSAIDs, steroids, prostaglandin analogues)
- Lyophilization
News & Updates
Company selected to present development status of sustained ocular drug delivery programs in inflammation, pain and glaucoma at the Ocular Innovation Summit (AAO event).
Announced completion and occupancy of a 10,000 sq ft facility in Bryan, Texas for global production of punctal plug products and initiation of Phase 3 trial manufacturing.
Purchased all rights related to the punctal plug delivery system from a prior rights-holder, eliminating future payment obligations tied to that transfer.
Company promoted executive to Chief Operating Officer to lead operating activities and prepare for commercial launch of punctal plug platform.
Peer-reviewed publication reporting Phase II randomized, masked, multi-center trial results showing significant reduction in post-operative pain and inflammation with a nepafenac formulation delivered via the punctal plug platform.
Publication of Phase II clinical data showing statistically significant improvements in pain, inflammation and visual acuity for nepafenac delivered by the punctal plug platform versus placebo.
Company selected to present development status of sustained ocular drug delivery programs in inflammation, pain and glaucoma at the Ocular Innovation Summit (AAO event).
Announced completion and occupancy of a 10,000 sq ft facility in Bryan, Texas for global production of punctal plug products and initiation of Phase 3 trial manufacturing.
Purchased all rights related to the punctal plug delivery system from a prior rights-holder, eliminating future payment obligations tied to that transfer.
Company promoted executive to Chief Operating Officer to lead operating activities and prepare for commercial launch of punctal plug platform.
Peer-reviewed publication reporting Phase II randomized, masked, multi-center trial results showing significant reduction in post-operative pain and inflammation with a nepafenac formulation delivered via the punctal plug platform.
Publication of Phase II clinical data showing statistically significant improvements in pain, inflammation and visual acuity for nepafenac delivered by the punctal plug platform versus placebo.